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group in elderly RA patients (≧65 years) and that even very 
low-dose glucocorticoid use (prednisolone 1–4 mg/day) 
is a risk factor for serious infections in biologics-treated 
elderly RA patients.
Keywords Rheumatoid arthritis · Biologic agents · 
Infection · Aging · Glucocorticoid
Introduction
Methotrexate (MTX) is an immunosuppressive non-bio-
logic disease-modifying antirheumatic drug (DMARD), 
which is used as a first-line drug for the treatment of rheu-
matoid arthritis (RA) [1, 2]. It has also been shown that 
long-term use of MTX does not appear to be a risk factor 
for serious infections in RA patients [3–6]. Biologic agents 
that block the effects of pro-inflammatory cytokines such 
as tumor necrosis factor (TNF) and IL-6 are used for the 
treatment of RA when disease activity can not be con-
trolled with conventional DMARDs including MTX and 
substantially improve outcomes of RA [1, 2]. However, 
biologic agents, due to their immunological properties, 
may increase the risk of serious infections in RA patients. 
Previous studies have reported that biologic agents increase 
the risk of serious infections in RA patients [7–10]. On the 
other hand, other studies have not found an increased risk 
of serious infections with biologic agents in RA patients [6, 
11, 12]. Thus, conflicting information still exists regarding 
the risk of serious infections with biologic therapy for RA.
Increasing age is also an important risk factor for infec-
tions. Aging generally induces age-related immune dys-
function, leading to the increased incidence and sever-
ity of infections [13, 14]. Furthermore, previous studies 
have shown that aging is one of the risk factors for serious 
Abstract This study aimed to determine whether the long-
term use of biologic agents increases serious infections 
in elderly patients with rheumatoid arthritis (RA) and to 
determine the risk factors of serious infections in biologics-
treated elderly RA patients. We retrospectively analyzed 
the incidence rate of serious infections that required hos-
pitalization between biologics-treated and non-biologic 
disease-modifying antirheumatic drug (DMARD)-treated 
elderly RA patients (aged over 65 years). We examined 
the risk factors for serious infections in biologics-treated 
elderly RA patients. We found that, during a 3-year obser-
vation period, the incidence rate of serious infections was 
not significantly different between biologics-treated and 
non-biologic DMARD-treated elderly RA patients [8.0 
(95% CI 4.7–13.5) and 6.3 (95% CI 4.1–9.5) events per 
100 person-years of follow-up, respectively, P = 0.78]. The 
time to the first serious infection did not significantly dif-
fer between the two groups by the analysis of the Kaplan–
Meier curves, either (P = 0.46). We then found that pred-
nisolone doses alone were significantly associated with 
serious infections in biologics-treated elderly RA patients. 
Furthermore, we found that prednisolone at 1–4 mg/day 
was associated with serious infections in biologics-treated 
patients, but not non-biologic DMARD-treated patients. On 
the other hand, prednisolone at greater than 5 mg/day was 
associated with serious infections in both biologics-treated 
and non-biologics-treated patients. We show that there is 
not a significant difference between the incidence of seri-
ous infections between biologics group and non-biologics 
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infections in RA patients [3, 6] and thus there are concerns 
that administration of biologic agents to elderly patients 
with RA may increase serious infections. However, there 
are only a few studies examining the risk of infections in 
the treatment of elderly RA patients with biologic agents. 
Schneeweiss et al. [15] found no significant increase in the 
incidence rate of serious bacterial infections in elderly RA 
patients receiving antiTNF therapy as compared with those 
receiving MTX therapy, although the length of follow-up 
was a relatively short term (1.3 and 0.6 years, respectively). 
Galloway et al. [9] found no increased in the elderly com-
pared to younger biologic patients. Therefore, the risk of 
long-term use of biologic agents for serious infections in 
elderly RA patients still remains largely unknown.
In this study, in order to determine whether the long-
term use of biologic agents increases serious infections in 
elderly RA patients, we retrospectively analyzed the inci-
dence rate of serious infections that required hospitaliza-
tion between biologics-treated and non-biologic DMARD-
treated elderly RA patients (aged over 65 years). Then, to 
determine the risk factors of serious infections in biologics-
treated elderly RA patients, we examined the background 
profiles between the patients suffering from serious infec-
tions and those without serious infections in biologics-
treated elderly RA patients.
Patients and methods
Patients and cohort analysis
We retrospectively reviewed electronic medical records 
of 183 sequential RA patients over the age of 65 years at 
the start date of follow-up whose therapy with or without 
biologics started between January 2006 and March 2012 
at Asahi General Hospital and analyzed the incidence of 
serious infections in the biologics group and non-biolog-
ics group of the patients. Serious infection was defined as 
infection requiring admission to the hospital or prolonga-
tion of hospitalization. All patients fulfilled the ACR 1987 
revised criteria for RA [16]. Our hospital was located in the 
rural area and had the only rheumatic disease center in the 
area. Consequently, most of our outpatients were admit-
ted to our hospital when they had serious adverse events 
including infection. For inclusion, we selected all elderly 
RA patients over the age of 65 years at the start of treat-
ments. Patients were seen regularly by rheumatologists to 
assess disease activity and disease severity and received 
routine clinical management. Observation period of a given 
patient was for 3 years from the initiation of the biologic 
or non-biologic therapy or from the initiation of the ther-
apy to the discontinuation of the therapy when it discon-
tinued before the 3-year observation period. Patients who 
lost follow-up due to moving or voluntary dropout were 
censored at the point. Patients who died during the obser-
vation period were censored at the point. Patients who had 
the treatment interruption of the biologic or non-biologic 
therapy were censored at that point. Patients who had the 
switching from biologic therapy to another biologic therapy 
were continued to observe in the biologics group. Similarly, 
patients who had the switching from non-biologic therapy 
to another non-biologic therapy were continued to observe 
in the non-biologics group.
Sixty-four elderly RA patients received biologic agents 
because their disease activities could not be controlled by 
conventional DMARDs treatment: 36 patients received 
TNF inhibitors including infliximab, etanercept, adali-
mumab, golimumab, and certolizumab, 6 patients received 
tocilizumab, and 22 patients were switched to other bio-
logic agents due to the ineffectiveness or adverse effects of 
initial biologic agents. One hundred and nineteen elderly 
RA patients received only DMARDs including methotrex-
ate (MTX) and sulfasalazine. DMARDs were also used in 
some patients of the biologics group. Glucocorticoids were 
used in some patients of both the biologics and non-biolog-
ics groups. Clinical and laboratory assessment at baseline 
included erythrocyte sedimentation rate (ESR), C-reactive 
protein (CRP), rheumatoid factor (RF), and comorbidities 
(Table 1). This study was approved by the Ethics Commit-
tee of Asahi General Hospital and was performed in accord-
ance with the principles of the Declaration of Helsinki.
Statistical analysis
Statistical analysis was performed using JMP software ver-
sion 9.0 (SAS Institute Japan, Tokyo, Japan). Normally dis-
tributed continuous data were analyzed using parametric 
tests (Student’s t test). Non-normally distributed data were 
analyzed using nonparametric tests (Mann–Whitney U test 
or Spearman’s rank correlation coefficient). Categorical 
data were analyzed using Chi-square test or Fisher’s exact 
test. The incidence rates were calculated and compared by 
the person-years method. Risk factors for serious infections 
were analyzed by multivariate analysis with the logistic 
regression model. Data of time to the serious infection were 
analyzed using the Kaplan–Meier method with log-rank 
test. P values less than 0.05 were considered significant.
Results
Baseline characteristics of the biologics 
and non‑biologics group in elderly RA patients
To evaluate the safety of long-term use of biologic agents 
in elderly RA patients, we retrospectively analyzed the 
371Rheumatol Int (2017) 37:369–376 
1 3
incidence of serious infections that required hospitaliza-
tion between the biologics (n = 64) and non-biologics 
group (n = 119) in elderly RA patients (≧65 years). Base-
line characteristics of the two groups are shown in Table 1. 
There were no significant differences in age (73.7 ± 5.1 vs 
73.7 ± 5.8 years), sex (female; 78.1 vs 69.7%) or disease 
duration (12.7 ± 9.7 vs 10.9 ± 13.3 years) between the 
biologics and non-biologics groups. There were no signifi-
cant differences in comorbidities including coexisting lung 
disease (32.8 vs 26.1%) and diabetes mellitus (4.7 vs 6.7%) 
between the two groups.
In RA medication, there was no significant difference 
in methotrexate (MTX) use (79.7 vs 79.8%) between the 
two groups. On the other hand, other DMARDs including 
sulfasalazine were used more frequently in the non-bio-
logics group (51.3%) than in the biologics group (32.8%, 
P = 0.016). Prednisolone (PSL) was used similarly in the 
two groups (1.8 ± 2.5 vs 1.9 ± 3.1 mg/day).
Incidence of serious infections is not different 
between the biologics and non‑biologics groups 
in elderly RA patients
We then examined the incidence of serious infections 
between the biologics and non-biologics groups in elderly 
RA patients (Table 2). During a 3-year observation period, 
the numbers of events of serious infections were not 
significantly different between the biologics and non-biolog-
ics groups (13 and 21, respectively). The numbers of patients 
with ≧1 events of serious infections were not significantly 
different between the two groups, either. The incidence of 
serious infections was 8.0 (95% CI 4.7–13.5) and 6.3 (95% 
CI 4.1–9.5) events per 100 person-years of follow-up in the 
biologics and non-biologics group, respectively, and was not 
significantly different between the two groups. The most fre-
quent infection was bacterial pneumonia with 6 infections in 
the biologics group and 12 infections in the non-biologics 
group (Table 2). Other common infections were cellulitis 
with three infections in the biologics group and two infec-
tions in the non-biologics group and pyelonephritis with one 
infection in the biologics group and three infections in the 
non-biologics group. In this cohort, there was no incidence 
of mycobacterium tuberculosis infection in either group.
Next, we analyzed the incidence of serious infections 
between the biologics and non-biologics groups using the 
Kaplan–Meier method (Fig. 1). The time to the first serious 
infection did not significantly differ between the two groups 
(Log-rank test P = 0.46). These results suggested that treat-
ment with biologic agents did not significantly increase the 
incidence of serious infections in elderly RA patients as 
compared with that with non-biologic agents. In the biolog-
ics group, 39 patients, including three patients who restarted 
biologic agents after recovery from serious infection, con-
tinued biologic agents during the observation period.
Table 1  Baseline 
characteristics of elderly RA 
patients
RF rheumatoid factor, DAS disease activity score, DMARDs disease-modifying antirheumatic drugs, PSL 
prednisolone
Characteristic Biologics (n = 64) Non-Biologics (n = 119) P
Age (years, mean ± SD) 73.7 ± 5.1 73.7 ± 5.8 0.92
Female, n (%) 50 (78.1%) 83 (69.7%) 0.22
Disease duration (years, mean ± SD) 12.7 ± 9.7 10.9 ± 13.3 0.34
RF positive, n (%) 57 (89.1%) 97 (81.5%) 0.18
ESR 60 (mm, mean ± SD) 60.6 ± 33.0 36.7 ± 28.7 <0.001
CRP (mg/L, mean ± SD) 27.9 ± 34.4 13.7 ± 35.6 0.011
Steinbrocker stage (I + II/III + IV) 32/32 71/48 0.23
Comorbidities, n (%)
 Coexisting lung disease 21 (32.8%) 31 (26.1%) 0.33
 Diabetes mellitus 3 (4.7%) 8 (6.7%) 0.58
Medications, n (%)
 Methotrexate 51 (79.7%) 95 (79.8%) 0.98
 Other DMARDs 21 (32.8%) 61 (51.3%) 0.016
 PSL (mg/day) 1.8 ± 2.5 1.9 ± 3.1 0.78
 PSL, any dose (%) 28 (43.7%) 44 (37.0%) 0.37
 PSL ≧5 mg/day 12 (18.7%) 27 (22.7%) 0.39
Biologics, n (%)
 TNF inhibitors 36 (56.2%)
 Tocilizumab 6 (9.4%)
 Switch of biologics 22 (34.4%)
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Of 25 patients who discontinued the treatment with bio-
logic agents, eight patients stopped biologic agents because 
of remission, seven patients stopped them because of seri-
ous infections, six patients stopped them because of insuf-
ficient effects, and four patients discontinued them because 
of the development of malignancies. There were three 
deaths in the biologics group (one serious infection and one 
unknown cause), while there were four deaths in the non-
biologics group (two serious infection, one lung cancer, 
and one arrhythmia).
Risk factors of serious infections in the biologics group 
of elderly RA patients
To determine the risk factors for serious infections in 
the biologics group of elderly RA patients, we examined 
the background profiles between the patients suffering 
from serious infections and those without serious infec-
tions in biologics-treated elderly RA patients (Table 3). 
There were no significant differences in age (74.5 ± 4.4 
vs 73.6 ± 5.3 years) or disease duration (15.4 ± 9.4 vs 
12.2 ± 9.7 years) between the patients with and without 
serious infections. Furthermore, there were no significant 
differences in the use of MTX (80.0 vs 79.6%) and other 
DMARDs (20.0 vs 35.2%) between the patients with and 
without serious infections. In addition, various biologic 
agents such as TNF inhibitors were used at a similar fre-
quency between the two patients groups (Table 3). However, 
we found that PSL dose (4.7 ± 3.2 vs 1.3 ± 2.0 mg/day, 
P < 0.001) and PSL use (90.0 vs 35.2%, P = 0.001) were 
significantly higher in the patients suffering from serious 
infections than those without serious infections (Table 3).
Table 2  Incidence of serious 
infections that required 
hospitalization in elderly RA 
patients
IQR interquartile range, ref. reference
Serious infections Biologics (n = 64) Non-biologics (n = 119) P
Number of events 13 21
Number of patients with ≧1 events 10 16 0.68
Biologics, OR (95% CI) 1.2 (0.5–2.8) 1.0 (ref.) 0.74
Observation period (months), median (IQR) 36 (26–36) 36 (31–36) 0.007
Rate, per 100 Person-years (95% CI) 8.0 (4.7–13.5) 6.3 (4.1–9.5) 0.78
Bacterial pneumonia, n 6 12
Cellulitis, n 3 2
Pyelonephritis, n 1 3
Pneumocystis pneumonia, n 1 0
Gastroenteritis, n 1 1
Bacterial arthritis, n 1 1
Viral infection, n 0 2
Fig. 1  Kaplan–Meier curves 
of incidence of serious infec-
tions between biologics and 
non-biologics groups in elderly 
RA patients. Time to the first 
serious infection that required 
hospitalization was analyzed 
using the Kaplan–Meier 
method. Incidence of serious 
infections is not significantly 
different between biologics and 
non-biologics groups in elderly 
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Low‑dose glucocorticoid increases the incidence 
of serious infections in the biologics group of elderly 
RA patients
We further analyzed the risk factors of serious infec-
tions in the biologics group of elderly RA patients using 
multivariate logistic regression analysis (Table 4). We 
selected age, biologic use, glucocorticoids use, DMARD 
use and coexisting lung disease as independent factors for 
multivariate logistic regression analysis based on previ-
ous reports [3, 4, 6, 17] and our present results (Table 3). 
Aging over the age of 75 years was not significantly asso-
ciated with serious infections in the biologics group of 
elderly RA patients (OR 1.1, 95% CI 0.2–5.3, P = 0.91). 
Biologics use was not significantly associated with seri-
ous infections (OR 1.1, 95% CI 0.4–3.2) in all elderly RA 
patients. PSL (≧5 mg/day) use was significantly associated 
with serious infections in the biologics group of elderly RA 
patients (OR 29.3, 95% CI 3.6–652.2, P < 0.001). Interest-
ingly, even lower doses of PSL (1–4 mg/day) use was sig-
nificantly associated with serious infections (OR 11.7, 95% 
CI 1.5–257.1, P = 0.02) in the biologics-treated patients. 
On the other hand, PSL (≧5 mg/day) use, but not PSL 
(1–4 mg/day) use, was significantly associated with serious 
infections in the non-biologics group of elderly RA patients 
(Table 4). These results suggest that even lower doses of 
glucocorticoid (PSL 1–4 mg/day) cause serious infections 
in biologics-treated patients than those do in the patients 
without biologics.
Discussion
In this retrospective cohort study, we show that there is not 
a significant difference in the incidence of serious infec-
tions between the biologics and non-biologics groups in 
elderly RA patients (≧65 years; Table 2 and Fig. 1). The 
most interesting observation is that glucocorticoid use is 
the most important risk factor for serious infections in bio-
logics-treated elderly RA patients (Table 3) and that even 
lower doses of glucocorticoid (PSL at <5 mg/day) increase 
the risk of serious infections in biologics-treated elderly 
RA patients, but not non-biologic DMARD-treated patients 
(Table 4).
We show that there is not a significant difference in the 
incidence of serious infections between the biologics and 
Table 3  Risk factors for serious infections in biologics group of 
elderly RA patients
IQR interquartile range, RF rheumatoid factor, DAS disease activity 
score, DMARDs disease-modifying antirheumatic drugs, PSL predni-
solone
Serious infection P
(+) (n = 10) (−) (n = 54)
Age (years, mean ± SD) 74.5 ± 4.4 73.6 ± 5.3 0.63
Female, n (%) 7 (70.0%) 43 (79.6%) 0.49
Disease duration (years, 
mean ± SD)
15.4 ± 9.4 12.2 ± 9.7 0.34
Observation period (months), 
median (IQR)
35 (21–36) 36 (27–36) 0.60
RF positive, n (%) 9 (90.0%) 48 (88.9%) 0.92
ESR 60 (mm, mean ± SD) 69.2 ± 43.7 59.2 ± 31.2 0.40
CRP (mg/L, mean ± SD) 29.3 ± 24.7 27.7 ± 36.0 0.89




 Coexisting lung disease 3 (30.0%) 18 (33.3%) 0.83
 Diabetes mellitus 0 (0%) 3 (5.5%) 0.44
Medications, n (%)
 Methotrexate 8 (80.0%) 43 (79.6%) 0.98
 Other DMARDs 2 (20.0%) 19 (35.2%) 0.34
 PSL (mg/day) 4.7 ± 3.2 1.3 ± 2.0 <0.001
 PSL, any dose (%) 9 (90.0%) 19 (35.2%) 0.001
 PSL ≧5 mg/day 6 (60.0%) 6 (11.1%) <0.001
Biologics, n (%)
 TNF inhibitors 4 (40.0%) 32 (59.2%) 0.10
 Tocilizumab 3 (30.0%) 3 (5.6%)
 Switch of biologics 3 (30.0%) 19 (35.2%)
Table 4  Multiple regression 
analysis of risk factors for 
serious infections in biologics 
and non-biologics group of 
elderly RA patients
All (n = 183) Biologics (n = 64) Non-biologics (n = 119)
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Aging ≧75 years 0.8 (0.3–2.1) 0.65 1.1 (0.2–5.3) 0.91 0.7 (0.2–2.4) 0.59
Biologics 1.1 (0.4–3.2) 0.78 – – – –
PSL none 1.0 (ref.) 1.0 (ref.) 1.0 (ref.)
1–4 mg/day 5.7 (1.5–24.2) 0.012 11.7 (1.5–257.1) 0.02 3.6 (0.4–24.5) 0.21
≧5 mg/day 21.5 (6.8–84.2) <0.001 29.3 (3.6–652.2) <0.001 19.2 (4.9–101.0) <0.001
DMARDs 0.7 (0.1–6.3) 0.70 0.2 (0.01–2.7) 0.21 – –
Coexisting lung disease 0.9 (0.3–2.5) 0.89 0.4 (0.03–2.5) 0.33 1.2 (0.3–4.3) 0.83
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non-biologics groups in elderly RA patients (≧65 years). 
We found that, during a 3-year observation period, the 
incidence rate of serious infections was not significantly 
different between the biologics and non-biologics groups 
in elderly RA patients (8.0 and 6.3 events per 100 person-
years of follow-up, respectively; Table 2). We also found 
that the time to the first serious infection did not signifi-
cantly differ between the two groups by the analysis of 
the Kaplan–Meier curves (Fig. 1). Among serious infec-
tions, bacterial pneumonia was the most frequent infection 
in both the biologics and non-biologics groups (Table 2), 
which is in agreement with previous studies [18, 19]. In 
addition, there was no significant difference in the inci-
dence of pneumocystis pneumonia between the two groups, 
although it has been shown that TNF inhibitors increase the 
incidence of opportunistic infections including pneumocys-
tis pneumonia and tuberculosis in RA patients [20–22]. As 
to mycobacterium tuberculosis, there was no incidence of 
tuberculosis in this study. We always checked the tubercu-
losis screening tests before starting biologic treatment and 
administered isoniazid if needed.
Recent evidence that combination therapy with TNF 
inhibitors and MTX for RA has superior efficacy to MTX 
therapy also suggests the possibility of an additive risk of 
infections in the combination therapy for RA [23]. How-
ever, several studies have shown that the rates of overall 
infections and serious infections do not significantly dif-
fer between combination therapy with TNF inhibitors 
and MTX and MTX monotherapy for RA [6, 11, 12, 24], 
whereas other studies have shown that the rate of serious 
infections is significantly higher in the combination therapy 
than MTX therapy [7, 8, 10]. It has been shown that disease 
activity is associated with the susceptibility for hospitalized 
infections in RA patients [25]. Although CRP and ESR 
were higher in the biologics group at the start of therapy 
than the non-biologics group (Table 1), improvements in 
physical limitations with biologic agents may counteract 
some of the immunosuppressive effects of these drugs [26]. 
In addition, older ages and comorbidities are also known to 
be risk factors for infections in RA patients [3, 6, 27], but 
ages and the rate of comorbidities (coexisting lung diseases 
and diabetes) were not significantly different between the 
biologic and non-biologic groups (Table 1). All subjects in 
this study were old (>65 years), and it probably minimized 
as an effect of age for infection in this study. Therefore, our 
results indicate that biologic agents together with conven-
tional DMARDs can be safely used for the treatment of 
elderly RA patients without increasing the risk of serious 
infections.
Second, our results show that even very low-dose gluco-
corticoid use (PSL 1–4 mg/day) significantly increases the 
risk of serious infections in biologics-treated elderly RA 
patients, but not non-biologic DMARD-treated patients. 
We found that PSL doses alone were significantly associ-
ated with serious infections in biologics-treated elderly 
RA patients (Table 3). Furthermore, we found that PSL 
1–4 mg/day was associated with serious infections in 
biologics-treated patients, but not non-biologic DMARD-
treated patients (Table 4). Our findings of the association of 
glucocorticoid use (PSL at >5 mg/day) with serious infec-
tions in both biologics-treated and non-biologics-treated 
patients (Table 4) are consistent with previous studies indi-
cating that glucocorticoid use is the most important risk 
factor for serious infections in RA patients, irrespective of 
biologics therapy and non-biologic DMARDs therapy [3, 
4, 6, 17]. Considering that 9/10 infections in the biologic 
cohort were on steroid, this observation deserves highlight-
ing. The fact that our patients received very low doses of 
PSL (biologics 1.8 mg/day and non-biologics 1.9 mg/day) 
in this cohort may contribute to the present findings. Thus, 
our results suggest that even very low-dose glucocorticoid 
use (PSL 1–4 mg/day) increases the susceptibility to seri-
ous infections in biologics-treated elderly RA patients.
This study was retrospective analysis and had several 
limitations. This study might not have detected a differ-
ence in the incidence of serious infections between both 
the groups because of inadequate sample size. Actually, 
the calculated power of biologic agents was 6.6% in this 
analysis. So, to prove the hypothesis that long-term use of 
biologic agents does not increase the risk of serious infec-
tions in elderly RA patients as compared with non-biologic 
DMARDs, a larger-scale registry study or cohort study 
will be required in the future. On the other hand, glucocor-
ticoids (none or use) had larger impact on serious infec-
tions (effect size d = 0.27) than glucocorticoids (none or 
use) and the calculated power was 55.0%. Glucocorticoids 
(PSL < 5 mg/day or PSL ≧ 5 mg/day) had larger impact 
on serious infections (effect size d = 0.40) than gluco-
corticoids (none or use) and the calculated power was 
72.4%. Second, the patients we analyzed might have been 
biased samples, because we could not choose to use bio-
logic agents for the treatment of patients with risk factors, 
including the known infections, respiratory dysfunction and 
poor performance status. Finally, the observation period 
was shorter in the biologics group than that in the non-bio-
logics group (Table 2). In the biologics group, the treatment 
with biologic agents was stopped in the situations in which 
patients achieved remission or had serious infections.
In conclusion, we show that there is not a significant dif-
ference in the incidence of serious infections between the 
biologics and non-biologics groups in elderly RA patients 
(≧65 years) and that even very low-dose glucocorticoid use 
(PSL 1–4 mg/day) is a risk factor for serious infections in 
biologics-treated elderly RA patients. Although our study 
has some limitations because of the retrospective cohort 
study and a relatively small sample size, these results 
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provide important information on the initiation and contin-
uation of biologic therapy in elderly RA patients.
Compliance with ethical standards 
Conflict of interest Hirotoshi Kawashima, Shin-ichiro Kagami, 
Daisuke Kashiwakuma, Kentaro Takahashi, Masaya Yokota, Shunsuke 
Furuta, and Itsuo Iwamoto declare that they have no conflict of interest.
Ethical approval “All procedures performed in studies involving 
human participants were in accordance with the ethical standards of 
the institutional and/or national research committee and with the 1964 
Declaration of Helsinki and its later amendments or comparable ethi-
cal standards.” Data obtained in this study did not interfere with course 
of treatment for patients included.
Human and animal rights This article does not contain any studies 
with animals performed by any of the authors.
Informed consent Informed consent was obtained from all individual 
participants included in the study.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://crea-
tivecommons.org/licenses/by/4.0/), which permits unrestricted use, 
distribution, and reproduction in any medium, provided you give 
appropriate credit to the original author(s) and the source, provide a 
link to the Creative Commons license, and indicate if changes were 
made.  
References
 1. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer 
JM et al (2012) 2012 update of the 2008 American College of 
Rheumatology recommendations for the use of disease-modify-
ing antirheumatic drugs and biologic agents in the treatment of 
rheumatoid arthritis. Arthritis Care Res 64:625–639
 2. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, 
Dougados M et al (2014) EULAR recommendations for the 
management of rheumatoid arthritis with synthetic and biologi-
cal disease-modifying antirheumatic drugs: 2013 update. Ann 
Rheum Dis 73:492–509
 3. Doran MF, Crowson CS, Pond GR, O’Fallon WM, Gabriel SE 
(2002) Predictors of infection in rheumatoid arthritis. Arthritis 
Rheum 46:2294–2300
 4. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM 
(2008) Use of nonbiologic disease-modifying antirheumatic 
drugs and risk of infection in patients with rheumatoid arthritis. 
Arthritis Rheum 59:1074–1081
 5. Salliot C, van der Heijde D (2009) Long-term safety of the meth-
otrexate monotherapy in patients with rheumatoid arthritis: a 
systemic literature research. Ann Rheum Dis 68:1100–1104
 6. Crowson CS, Hoganson DD, Fitz-Gibbon PD, Matteson EL (2012) 
Development and validation of a risk score for serious infection in 
patients with rheumatoid arthritis. Arthritis Rheum 64:2847–2855
 7. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, 
Montori V (2006) Anti-TNF antibody therapy in rheumatoid 
arthritis and the risk of serious infections and malignancies: sys-
tematic review and meta-analysis of rare harmful effects in rand-
omized controlled trials. JAMA 295:2275–2285
 8. Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, 
Feltelius N et al (2007) Time dependent increase in risk of hos-
pitalization with infection among Swedish RA patients treated 
with TNF antagonists. Ann Rheum Dis 66:1339–1344
 9. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustian-
owski AP et al (2011) Anti-TNF therapy is associated with an 
increased risk of serious infections in patients with rheumatoid 
arthritis especially in the first 6 months of treatment: updated 
results from the British Society for Rheumatology Biologics 
Register with special emphasis on risks in the elderly. Rheuma-
tology (Oxford) 50:124–131
 10. Curtis JR, Xie F, Chen L, Baddley JW, Beukelman T, Saag KG 
et al (2011) The comparative risk of serious infections among 
rheumatoid arthritis patients starting or switching biological 
agents. Ann Rheum Dis 70:1401–1406
 11. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Sym-
mons DP et al (2006) Rates of serious infection, including 
site-specific and bacterial intracellular infection, in rheumatoid 
arthritis patients receiving anti-tumor necrosis factor therapy: 
results from the British Society for Rheumatology Biologics 
Register. Arthritis Rheum 54:2368–2376
 12. Grijalva CG, Chen L, Delzell E, Baddley JW, Beukelman T, 
Winthrop KL et al (2011) Initiation of tumor necrosis factor-α 
antagonists and the risk of hospitalization for infection in 
patients with autoimmune diseases. JAMA 306:2331–2339
 13. Gavazzi G, Krause KH (2002) Ageing and infection. Lancet 
Infect Dis 2:659–666
 14. Grubeck-Loebenstein B, Berger P, Saurwein-Teissl M, Zisterer 
K, Wick G (1998) No immunity for the elderly. Nat Med 4:870
 15. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, 
Sax PE (2007) Anti-tumor Necrosis Factor α therapy and the risk 
of serious bacterial infections in elderly patients with rheumatoid 
arthritis. Arthritis Rheum 56:1754–1764
 16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, 
Cooper NS et al (1998) The American Rheumatism Association 
1987 revised criteria for the classification of rheumatoid arthritis. 
Arthritis Rheum 31:315–324
 17. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa 
MA et al (2008) The risk of hospitalized infection in patients 
with rheumatoid arthritis. J Rheumatol 35:387–393
 18. Wolfe F, Caplan L, Michaud K (2006) Treatment for rheumatoid 
arthritis and the risk of hospitalization for pneumonia; associa-
tion with prednisone, disease-modifying antirheumatic drugs, and 
anti-tumor necrosis factor therapy. Arthritis Rheum 54:628–634
 19. Kroesen S, Widmer AF, Tyndall A, Hasler P (2003) Serious bac-
terial infections in patients with rheumatoid arthritis under anti-
TNF-α therapy. Rheumatology (Oxford) 42:617–621
 20. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, 
Schweiterman WD et al (2001) Tuberculosis associated with inf-
liximab, a tumor necrosis factor α—neutralizing agent. N Engl J 
Med 345:1098–1104
 21. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero 
MD, BIOBADASER Group (2003) Treatment of rheumatoid 
arthritis with tumor necrosis factor inhibitors may predispose 
to significant increase in tuberculosis risk: a multicenter active-
surveillance report. Arthritis Rheum 48:2122–2127
 22. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, 
Yamanaka H et al (2008) Postmarketing surveillance of the 
safety profile of infliximab in 5000 Japanese patients with rheu-
matoid arthritis. Ann Rheum Dis 67:189–194
 23. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon 
JM, Emery P et al (2004) Combination of infliximab and metho-
trexate therapy for early rheumatoid arthritis: a randomized, con-
trolled trial. Arthritis Rheum 50:3432–3443
 24. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, 
Zheng C et al (2010) Association of methotrexate and tumor 
376 Rheumatol Int (2017) 37:369–376
1 3
necrosis factor antagonists with risk of infectious outcomes 
including opportunistic infections in the CORRONA registry. 
Ann Rheum Dis 69:380–386
 25. Au K, Reed G, Curtis JR, Kremer JM, Greenberg JD, Strand V 
et al (2011) High disease activity is associated with an increased 
risk of infection in patients with rheumatoid arthritis. Ann 
Rheum Dis 70:785–791
 26. Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ, 
Klopsch T, Zink A et al (2011) Treatment benefit or survival of 
the fittest: what drives the time-dependent decrease in serious 
infection rates under TNF inhibition and what does this imply 
for the individual patient? Ann Rheum Dis 70:1914–1920
 27. Listing J, Gerhold K, Zink A (2013) The risk of infections asso-
ciated with rheumatoid arthritis, with its comorbidity and treat-
ment. Rheumatology (Oxford) 52:53–61
